This strategy enables Pfizer to maintain a strong foothold in the generic drug market while also protecting its revenue ...

Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.

SHELTON, CT / ACCESS Newswire / February 11, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company") declared today that it is ready to fight the bird flu with ...

At the 63rd Annual Day Celebrations of the Indian Drug Manufacturers Association (IDMA) in Mumbai recently, Dr Rajeev Raghuvanshi, Drugs Controller General of India (DCGI), delivered a compelling ...

Arrowhead Pharmaceuticals, Inc. ( NASDAQ: ARWR) Q1 2025 Earnings Conference Call February 10, 2025 4:30 PM ET Chris Anzalone - President & CEO Bruce Given - Interim Chief Medical Scientist Andy Davis ...

Biopharmaceutical Contract Manufacturing Market Biopharmaceutical Contract Manufacturing Learn how outsourcing trends in biopharma m ...